Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

• Published in: JGH open : an open access journal of gastroenterology and hepatology Vol. 7; no. 12; pp. 1012 - 1015
• Main Authors: Hilley, Patrick, Con, Danny, Choy, Matthew C, Srinivasan, Ashish, De Cruz, Peter
• Format: Report
• Language: English
• Published: 01-12-2023
• ISSN: 2397-9070
• DOI: 10.1002/jgh3.13015

Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min/1.73m2. Upadacitinib, a selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy in the management of moderate to severe ulcerative colitis. There is also emerging data indicating that JAK inhibition may be clinically effective in the setting of steroid-refractory acute severe ulcerative colitis (ASUC). There is, however, a lack of "real-world" data documenting the use of JAK inhibitors in patients with ESRD. Here, we report the use of upadacitinib in a patient with ESRD for the management of steroid-refractory ASUC, demonstrating, for the first time, the safe and clinically effective use of upadacitinib in this population.